Physician profile
Jonathan D Bier
NPI 1306883343
$1,365.40
in general payments reported to CMS, 2019-2025
22 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $13.20 · 2023: $39.23 · 2024: $440 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $242.02 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $174.77 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $93.65 | 2024-2025 | Opsumit, Opsynvi |
| Terumo Medical Corporation | $77.43 | 2019 | |
| Alnylam Pharmaceuticals INC. | $75.00 | 2025 | Onpattro, Amvuttra |
| Janssen Pharmaceuticals, INC | $74.36 | 2024 | Xarelto |
| Medtronic Vascular, INC. | $68.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $64.15 | 2024-2025 | Farxiga |
| Amgen INC. | $57.44 | 2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $54.83 | 2024-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $49.85 | 2024-2025 | Cardiomems, Amplatzer Amulet |
| Edwards Lifesciences Corporation | $45.90 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $43.18 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.12 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $39.91 | 2024-2025 | Verquvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $32.09 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $27.54 | 2025 | Attruby |
| Philips North America LLC | $27.50 | 2025 | Lm Undivided |
| Boston Scientific Corporation | $23.49 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.18 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $20.02 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.54 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.